Affordable Access

Decreased production of soluble interleukin 2 receptor by phytohaemagglutinin-stimulated peripheral blood mononuclear cells in patients with breast cancer after adjuvant therapy.

Authors
Journal
British Journal of Cancer
0007-0920
Publisher
Nature Publishing Group
Publication Date
Keywords
  • Research Article
Disciplines
  • Biology
  • Medicine

Abstract

Br. J.Cne 18) 0 1 1 TeMcilnPesLd,18 SHORT COMMUNICATION Decreased production of soluble interleukin 2 receptor by phytohaemagglutinin-stimulated peripheral blood mononuclear cells in patients with breast cancer after adjuvant therapy C.C. Zielinski, Ch. Muller', E Tichatschek & P. Aiginger II Department of Medicine and 'II Department of Gastroenterology and Hepatology, University Hospital, and the Ludwig Bolt-mann Institut fiir prdnatale und experimentelle Genomanalytik, A-1090 Vienna, Austria. Adjuvant chemotherapy has become an universally accepted approach to certain patients with breast cancer in that it has resulted in a prolongation of the disease-free interval (DFI) in defined subgroups (Consensus Development Conference Committee, 1986; Editorial, 1986). However, long-term side effects of adjuvant cytostatic measures have not been clearly defined (Consensus Development Conference Committee, 1986). Recently, we have reported a prolonged effect of adjuvant chemotherapy with cyclophosphamide, methotrex- ate and fluoruracil (CMF; Bonadonna et al., 1977) in era- dicating primary antibody production (Zielinski et al., 1986) and, like other authors (Blomgren et al., 1980; Levy et al., 1987), we have reported changes in natural killer cell activity after adjuvant treatment (Tichatschek et al., 1988). We have now investigated the impact of adjuvant radio- and/or chemotherapy in breast cancer upon T cell activation (Rubin et al., 1985), and have studied soluble interleukin 2 receptor (sIL-2R) concentrations in serum and in super- natants of phytohaemagglutinin (PHA) stimulated peripheral blood mononuclear cells (PBMC) derived from patients with breast cancer after various adjuvant treatment modalities. A total of 54 female patients (mean age: 59.2±2.3 years) with breast cancer was included in the study. The patients consisted of two groups as follows. Group 1 contained 31 patients with stage II breast cancer in the DFI without clinical or serological signs of metastases up to 6 months after bei

There are no comments yet on this publication. Be the first to share your thoughts.